April 15, 2020—Abbott announced today the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the IgG antibody that identifies if a person has had COVID-19. The test adds to Abbott’s existing COVID-19 tests that are in use, including its m2000 molecular laboratory system and ID Now molecular point-of-care device.
The SARS-CoV-2 IgG antibody test will initially be available on the company’s Architect i1000SR and i2000SR laboratory instruments, which can run up to 100 to 200 tests per hour.
Abbott expects to ship close to 1 million tests this week to U.S. customers and will ship 4 million tests in April and up to 20 million tests in June and beyond, as it expands the tests to run on its Alinity i system. The company plans to add a SARS-CoV-2 IgM antibody test in the near future.